ACVR1 and myelofibrosis: Momelotinib is a JAK1/JAK2/activin receptor type-1 (ACVR1) ATP-competitive inhibitor that is being investigated in patients with myelofibrosis who have failed previous jakinib therapy (NCT01969838) [97].